Research & Development: Page 5
-
Stock via Getty Images
An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped?
Cassava Sciences’ beleaguered investigational Alzheimer’s therapy is in two phase 3 studies.
By Meagan Parrish • Oct. 4, 2024 -
iStock via Getty Images
How Roche plans to fill a projected $8B sales gap
Biosimilar competition will erode billions from the pharma giant’s top line in the next few years.
By Amy Baxter • Oct. 2, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineRare diseases
As drug developers find promise in the rare diseases, deals and treatments are on the rise
By PharmaVoice staff -
Honglouwawa via Getty Images
Kailera Therapeutics emerges from stealth with $400M for obesity drugs
The official launch comes five months after a filing indicated major investors such as Atlas Venture and Bain Capital were backing the biotech, then named “Hercules CM NewCo.”
By Gwendolyn Wu • Oct. 2, 2024 -
Permission granted by Biocom
Q&ACalifornia is a life sciences leader. Joe Panetta has been one of its most vocal advocates.
The president and CEO of Biocom California discusses the state’s strengths and weaknesses, current and emerging hubs, and the industry’s future.
By Alexandra Pecci • Oct. 1, 2024 -
Stock via Getty Images
After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum?
The company’s allogeneic therapy was OK’d in the EU and could become the first of its kind approved by the FDA in January — while eyeing the next frontier.
By Kelly Bilodeau • Sept. 30, 2024 -
Stock via Getty Images
Behind the rise of BMS’ Cobenfy, the first new schizophrenia drug in decades
The FDA OK for KarXT, now known as Cobenfy, demonstrates Bristol Myers Squibb’s dealmaking prowess and marks a turning point for a new generation of treatments.
By Kelly Bilodeau • Sept. 26, 2024 -
Permission granted by Roivant Sciences
Q&ARoivant’s magic trick: Finding the ‘weird-shaped’ pieces around Big Pharma’s cookie cutters
Roivant CEO Matt Gline leads the company on a unique path by placing bets on misfit drugs and technologies — and it’s working.
By Michael Gibney • Sept. 26, 2024 -
Stock via Getty Images
Fresh data intensifies race for a major gene therapy target
4D Molecular Therapeutics reported positive interim analysis in the high-potential wet AMD indication last week.
By Meagan Parrish • Sept. 25, 2024 -
Permission granted by CRI
Q&A // First 90 DaysWant better cancer treatments? Make biopharma more like Silicon Valley
Alicia Zhou brings startup bona fides to the nonprofit Cancer Research Institute to promote defragmentation of the cancer research effort.
By Michael Gibney • Sept. 24, 2024 -
Permission granted by Ovid Therapeutics
After epilepsy setback, Ovid charges confidently ahead in CNS
A promising epilepsy drug Ovid sold to Takeda recently missed the mark in late-stage trials. But Ovid believes it has other novel mechanisms that could deliver a CNS win.
By Meagan Parrish • Sept. 20, 2024 -
iStock via Getty Images
At J&J, oncology R&D meets commercial strategy in a quest for new standards of care
The disparate teams of research and commercial at J&J work closely together from the get-go.
By Michael Gibney • Sept. 19, 2024 -
Sarah Silbiger via Getty Images
Getting IND ready — how companies can avoid common traps
Overpromising, overcommitting and neglecting CMC are a few of the pitfalls that cause sponsors to stumble when submitting a new drug application.
By Alexandra Pecci • Sept. 18, 2024 -
iStock via Getty Images
How a radiopharma up-and-comer builds momentum in a surging space
Big Pharma is embracing the radiopharmaceuticals boom that was a long time in the making.
By Michael Gibney • Sept. 17, 2024 -
Stock via Getty Images
The hunt for game-changers against the deadliest form of brain cancer
Treatments for glioblastoma have fallen short in the face of difficult challenges, but the pipeline is full of renewed attempts.
By Kelly Bilodeau • Sept. 16, 2024 -
Stock via Getty Images
Who’s winning in biotech’s tight market?
Three of the largest fundraising rounds in 2024 show where investors are willing to place their bets in biotech.
By Meagan Parrish • Sept. 13, 2024 -
Permission granted by Sanofi
3 FDA approval dates to watch in the year’s final push
A handful of potential blockbusters are marching toward FDA review.
By Amy Baxter • Sept. 11, 2024 -
Permission granted by Organon
Why pharma should redefine ‘women’s health’
A broader approach recognizes the challenges disproportionately impacting women and could lead to better outcomes, according to Organon.
By Alexandra Pecci • Sept. 11, 2024 -
George Frey/Reuters
Deep DiveA decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology
Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.
By Jonathan Gardner • Sept. 10, 2024 -
Getty Images via Getty Images
Huntington’s disease R&D is regaining ground after several disappointments
Setbacks haven’t stopped advances by biotechs and pharmas working on new drugs for the inherited brain disorder.
By Kelly Bilodeau • Sept. 9, 2024 -
Scott Olson via Getty Images
Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies
The deal, which targets metabolic diseases, is one of a few by Big Pharma to develop lncRNA therapies.
By Amy Baxter • Sept. 9, 2024 -
Stock via Getty Images
What 3 layoff stories reveal about pharma’s troubles
The factors driving the industry’s layoffs — and what could help turn the tide.
By Meagan Parrish • Sept. 6, 2024 -
Permission granted by Pfizer
A plucky biotech threatening Pfizer’s grip on the Prevnar vaccine market
Results from Vaxcyte’s clinical pneumococcal vaccine study showed the smaller company could take on Pfizer’s legendary blockbuster.
By Michael Gibney • Sept. 4, 2024 -
Stock via Getty Images
Pharma’s ‘it’ therapy — a new drug class gaining steam
More companies are investing in protein degraders, which leverage a unique approach to harnessing the immune system in cancer, neurological diseases and more.
By Kelly Bilodeau • Sept. 4, 2024 -
Getty Images via Getty Images
Their Alzheimer’s treatment worked — but shares fell anyway
Cognition Therapeutics touted what the C-suite saw as a promising mid-stage study in Alzheimer’s, but investors read a different story.
By Michael Gibney • Aug. 29, 2024 -
Stock via Getty Images
After an FDA rejection, here’s what’s next in the psychedelics pipeline
By rejecting the first MDMA therapy earlier this month, the FDA signaled to the psychedelic drug sector that the road to approval isn’t clear cut.
By Amy Baxter • Aug. 28, 2024
Previous
